Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital

Core Viewpoint - Singular Genomics Systems, Inc. has received an unsolicited non-binding acquisition proposal from Concentra Biosciences, LLC to acquire all outstanding shares for $12.00 per share in cash [1] Group 1: Acquisition Proposal - Concentra has proposed to acquire Singular Genomics for $12.00 per share in cash, with an alternative option for stockholders to receive a contingent value right [1] - The proposal was disclosed in a Schedule 13D filed with the SEC, indicating that Tang Capital, the controlling stockholder of Concentra, owns approximately 14.9% of Singular Genomics' outstanding common stock [2] Group 2: Special Committee - Singular Genomics' board of directors has formed a special committee of independent directors to evaluate the acquisition proposal from Concentra along with other potential proposals [3] Group 3: Advisors - TD Cowen is serving as the financial advisor to the Special Committee, while Richards, Layton & Finger, P.A. and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP are providing legal advisory services [5] Group 4: Company Overview - Singular Genomics is a life science technology company focused on next-generation sequencing and multiomics technologies, with products like the G4® Sequencing Platform and the upcoming G4X™ Spatial Sequencer [6]